Gabapentin Capsule
Product Images NDC 45963-555

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 45963-555). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

A formula for calculating creatinine clearance (CLCr) based on age, weight, sex, and serum creatinine levels. It is not specific to any drug but represents a clinical equation component.*

FDA Label Image

1 (Image 10)

FDA Label Image

1 (Image 11)

FDA Label Image

1 (Image 12)

FDA Label Image

1 (Image 13)

Label for Gabapentin Capsules USP 100 mg, a drug for further processing provided by Actavis Pharma, Inc. The label states the package contains 100 capsules and includes pharmacist dispensing instructions. It lists storage conditions, manufacturing details by Watson Pharma Private Limited in India, and contact information for Teva Pharmaceuticals in Parsippany, NJ. A barcode and serialization coding area are also visible.*

FDA Label Image

1 (Image 14)

Label for Gabapentin Capsules, USP 300 mg by Actavis Pharma, Inc. The label shows a container of 100 capsules. It includes storage instructions, manufacturer details (Watson Pharma Private Limited, India), and dispensing guidance, featuring the Teva logo and a barcode.*

FDA Label Image

1 (Image 15)

Gabapentin Capsules, USP 400 mg label from Actavis Pharma, Inc. The label specifies dispensing instructions, storage conditions, and manufacturer information. It indicates the product contains 100 capsules and directs pharmacists to provide the accompanying Medication Guide to patients. The label features the Teva logo and includes barcode and serialization areas.*

FDA Label Image

1 (Image 2)

Chemical structure of Gabapentin depicted as a 2D molecular diagram showing carbon, nitrogen, oxygen, and hydrogen atoms arranged in the characteristic shape of the active ingredient Gabapentin.*

FDA Label Image

1 (Image 3)

FDA Label Image

1 (Image 4)

FDA Label Image

1 (Image 5)

Chemical structure diagram of gabapentin, showing a cyclohexane ring with amino (CH2NH2) and carboxymethyl (CH2CO2H) side groups attached to the ring.*

FDA Label Image

1 (Image 6)

Line graph depicting mean pain scores over 8 weeks for a placebo group and a Gabapentin 3600 mg/day group. The x-axis represents weeks, including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Gabapentin group scores decrease over time, while placebo scores remain relatively stable.*

FDA Label Image

2 (Image 7)

A line graph showing the mean pain score over seven weeks for placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows pain scores ranging from 0 to 10. Gabapentin groups show a greater reduction in pain scores compared to placebo over time.*

FDA Label Image

3 (Image 8)

A bar graph comparing percentage outcomes between placebo (PBO) and Gabapentin (GBP) at different dosages across two studies. Study 1 shows PBO at 12% and GBP 3600 at 29%. Study 2 shows PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance is indicated with p values less than 0.01 and 0.001.*

FDA Label Image

4 (Image 9)

A scatter plot showing difference percentages on the y-axis versus daily dose in mg on the x-axis. The graph compares results from three studies labeled as Study a, Study b, and Study c across doses of approximately 600 mg, 900 mg, 1200 mg, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.